Ioflupane (123i) Rotop

Ioflupane, the active ingredient in Ioflupane (123i) Rotop, is a radiopharmaceutical presented as an injection solution for intravenous use. It is employed to evaluate Parkinsonian syndromes and other movement disorders by visualizing dopaminergic neuron integrity. GNH USA supplies Ioflupane (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Ioflupane (123i) Rotop is a radiopharmaceutical used in the assessment of dopaminergic pathways for neurological disorders. - Parkinsonian syndromes: enables visualization of presynaptic dopamine transporter loss to support diagnosis. - Parkinson's disease differential diagnosis: helps distinguish Parkinson's disease from other movement disorders. - Movement disorder assessment: provides quantitative data on dopamine transporter availability for clinical decision‑making.

Ioflupane is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain or erythema - Nausea or mild vomiting - Headache - Dizziness or light‑headedness - Transient hypotension - Flushing

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Significant hypotension requiring medical intervention - Radiation‑induced skin injury at the injection site - Pulmonary edema - Cardiac arrhythmias - Severe nausea or vomiting leading to dehydration

Use of Ioflupane requires careful consideration of patient‑specific factors and handling requirements. - Pregnancy: safety not established; avoid unless essential. - Breastfeeding: unknown excretion; consider discontinuation of nursing. - Renal impairment: assess renal function as clearance may be altered. - Radiation exposure: limit cumulative dose and follow radiation safety guidelines. - Contraindications: known hypersensitivity to Ioflupane or any component of the formulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with other agents that affect dopaminergic imaging or iodine handling.

Major Interactions (Avoid): - MAO‑B inhibitors: can modify tracer uptake and confound interpretation. - D2‑receptor antagonists (typical antipsychotics): may reduce DAT binding visibility. - Concurrent radiopharmaceuticals with overlapping emission spectra: can interfere with SPECT image quality.

Moderate Interactions (Monitor Closely): - Iodinated contrast agents used in CT/MRI: may affect subsequent Ioflupane imaging. - Thyroid hormone therapy: may alter iodine metabolism and tracer distribution. - Drugs affecting renal excretion (e.g., loop diuretics): monitor for altered clearance.